Victory Capital Management Inc. Purchases 21,764 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Victory Capital Management Inc. raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,928,715 shares of the company’s stock after purchasing an additional 21,764 shares during the quarter. Victory Capital Management Inc. owned 0.17% of Teva Pharmaceutical Industries worth $34,755,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Maple Rock Capital Partners Inc. increased its position in shares of Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after acquiring an additional 1,770,000 shares in the last quarter. National Pension Service boosted its stake in Teva Pharmaceutical Industries by 107.3% during the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after purchasing an additional 1,640,940 shares during the last quarter. Iron Triangle Partners LP increased its holdings in Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after purchasing an additional 1,469,864 shares in the last quarter. Driehaus Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth approximately $23,115,000. Finally, Davidson Kempner Capital Management LP lifted its holdings in shares of Teva Pharmaceutical Industries by 152.5% in the second quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock valued at $28,689,000 after purchasing an additional 1,066,150 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.43 on Friday. The firm has a market cap of $18.61 billion, a P/E ratio of -19.33, a price-to-earnings-growth ratio of 1.32 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The company’s 50 day moving average is $17.78 and its 200-day moving average is $17.22. Teva Pharmaceutical Industries Limited has a 12-month low of $8.64 and a 12-month high of $19.31.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.